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Introduction 
Patients with Lynch Syndrome are at a high risk of 
developing multiple cancers, including cancers of the colon 
or rectum, uterus, small bowel, stomach, renal pelvis, urether, 
biliary tract, ovaries, brain and pancreas (1).
The most commonly observed tumors in patients with 
Lynch Syndrome are colorectal and endometrial cancers. 
This autosomal dominantly inherited disease arises as a result 
of a germline mutation in one of several mismatched repair 
(MMR) genes. MLH-1 and MSH-2 account for 90% of all 
identified mutations. Herein, we report the case of a patient 
with a neuroendocrine tumor (NET) demonstrating lack of 
MLH-1 expression. Since her gastric adenocarcinoma also 
demonstrated lack of MLH-1 expression and the patient 
harbored a germline mutation in MLH-1, her NET likely 
developed as a consequence of the Lynch Syndrome.
Case report
CB is a 63 year old woman with a previous history of 
adenocarcinoma of the colon diagnosed at age 52 and 
adenocarcinoma of the stomach diagnosed at age 57, 
each treated with surgery. Recently she presented with 
increasing abdominal pain and a 150 pound unintentional 
weight loss which developed over the preceding 5 years. An 
abdominal and pelvic MRI demonstrated three liver lesions 
suspicious for malignancy which were not seen on scanning 
6 years earlier. And ultrasound-guided liver biopsy showed 
a “Neuroendocrine Neoplasm, High Grade” which was 
immunohistochemically (IHC) positive for synaptophysin, 
pankeratin, CD56, and chromogranin, confirmimg 
the diagnosis. Colonoscopy and upper endoscopy were 
performed and a mass was identified in the gastric remnant. 
A biopsy of the mass confirmed recurrent adenocarcinoma of 
the stomach.
The patient was seen by the clinical genetics service and 
a germline mutation in MLH-1 [(K618del) (1852del3)] 
was identified. The germline mutation described was 
characterized as a deleterious mutation by Myriad Genetics 
Laboratories (Salt Lake City, UT) where the assay was done. 
Both the NET and the gastric cancer demonstrated lack of 
expression of MLH-1. The patient received carboplatin and 
etoposide (one cycle) followed by cisplatin and etoposide 
(5 cycles) chemotherapy for a total of 6 cycles. Repeat MRI 
showed improvement in the liver lesions after two cycles. A 
PET/CT scan reportedly showed no increase PET avidity 
in the liver. The patient underwent surgery with resection of 
residual adenocarcinoma of the stomach and all suspicious 
liver lesions. No residual malignancy was seen histologically 
in the liver lesions removed. 
Discussion
Inheritance of certain germline mutations in MMR genes 
now defines the Lynch Syndrome and results in an increased 
risk of a variety of malignancies. The patient described above 
was diagnosed with colon cancer, gastric cancer and most 
recently a NET. The diagnosis of the NET was confirmed 
histologically and with IHC. 
Patients with apparent Lynch Syndrome who had 
an adenocarcinoma and a neuroendocrine tumor or an 
adenocarcinoma with neuroendocrine features have 
been reported. For example, a patient with a colon 
adenocarcinoma and an appendix carcinoid tumor was 
described (2). However, while the colon adenocarcinoma 
showed microsatellite instability (MSI), the carcinoid did not. 
Therefore, the authors themselves concluded that these two 
tumors “arose through different molecular pathways”. Others 
have also noted a small number of cases of carcinoid tumors 
seen in association with Lynch Syndrome, but those tumors 
were not tested for lack of MMR expression or MSI, features 
that would more highly suggest that the carcinoids were in 
fact a result of a germline mutation in an MMR gene (3). In 
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another case report an adenocarcinoma with neuroendocrine 
features that lacked MSH-2 expression was described (4). 
However, this was not a neuroendocrine tumor, but rather 
an adenocarcinoma with neuroendocrine features. In still 
another report, a pancreatic endocrine neoplasm lacked 
expression of a mismatch repair gene product (MSH2/
MSH6) (5). However, germline testing for this mutation was 
not performed in that patient. Our patient demonstrated a 
deleterious germline mutation in an MMR gene (MLH-1) 
and both her adenocarcinoma and neuroendocrine tumors 
showed lack of expression of MLH-1, supporting the Lynch 
Syndrome as predisposing to the development of each tumor.
While it is possible that the gastric adenocarcinoma 
differentiated into a neuroendocrine tumor and then 
metastasized, there were no neuroendocrine features in the 
gastric adenocarcinoma. Also, in the liver metastases, which 
were biopsied and eventually removed, the pathologist noted 
that the gastric and liver lesions were morphologically and 
histochemically distinct and there were no adenocarcinoma 
features in the neuroendocrine tumor. Therefore it would 
seem unlikely that the metastasis in the liver arose from the 
gastric adenocarcinoma. It is also possible that the gastric 
adenocarcinoma represented a new primary, rather than a 
recurrent adenocarcinoma. Regardless, aside from lacking 
MLH-1 expression, the adenocarcinoma was otherwise 
immunohistochemically and morphologically different 
from the NET. It also remains possible that our patient’s 
neuroendocrine tumor was unrelated to her germline 
mutation in MLH-1, although there is little evidence 
that lack of expression of MLH-1 occurs in sporadic 
neuroendocrine tumors (6).
Lynch Syndrome due to inheritance of germline mutations 
in MMR genes represents the most common inherited 
colorectal cancer syndrome. In our patient, a deleterious 
germline mutation in MLH-1 was seen with lack of MLH-
1 expression in both a NET and a distinct adenocarcinoma. 
This case report suggests that Lynch Syndrome may 
predispose to NET development.
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